Metapneumovirus infection in children in modern conditions: clinical and immunological parallels

Aim. The study of metapneumovirus infection clinical and immunological features in children of different ages. Patients and methods. An analysis of 22 patients with mono-metapneumovirus infection is presented. There were 7 (31.8%) children under the age of 1 year, 8 (36.4%) — 1—3 years old, 7 (31.8%) — 4—7 years old. Diagnosis of metapneumovirus infection was based on clinical data and on PCR analysis of nasopharyngeal mucus. Immunological studies in 10 patients included immunophenotype of patient's blood lymphocytes and analysis of the interferon system. Results. Among children under the age of 1 year 71.4 ± 17.1% were diagnosed with obstructive bronchitis and 28.6 ± 17.1% had pneumonia. In patients aged 1—3 years pneumonia was observed more often (55.6 ± 17.6%), obstructive bronchitis — less often (33.3 ± 16.7%), and in 11.1 ± 11.1% bronchitis occurred without symptoms of bronchial obstruction. In children aged 4—7 years only the upper respiratory tract was affected in 14.3 ± 13.2% of cases, 57.1 ± 18.7% developed bronchitis and 28.6 ± 17.1% — pneumonia. The immune system state was characterized by a low content of T-helpers (CD3 + CD4 + ) and NK-cells (CD3-CD16 + CD56 + ) detected in 7 (70%) and 5 (50%) patients respectively. IFNγ production was reduced in 70% of children and IFNα in 80%. Conclusion. Metapneumovirus infection in children in modern conditions is characterized by the frequent development of inflammatory changes in the bronchopulmonary system in the early stages of the disease. The disease severity was due to both manifestations of respiratory failure and severe symptoms of intoxication. Immunological studies revealed changes in the cellular link and the interferon system in all age groups.

1. Khmilevskaya S.A., Zryachkin N.I., Mikhailova V.E. Clinical-epidemiological peculiarities of acute respiratory infections in children from 3 to 12 years and evaluation of effectiveness of antivirus therapy. Zhurnal infektologii=Journal Infectology. 2017; 9(1):17—21. (in Russ.). doi:10.22625/2072-6732-2019-11-3-38-45

2. Sominina A.A., Pisareva M.M., Buzitskaya Zh.V., Osidak L.V., Sukhovetskaya V.F., Afanasyeva O.I. et al. Peculiarities of etiology of respiratory virus infections in hospitalized patients depending on the demographic, socioeconomic factors and previous vaccination. Epidemiologiya i vaktsinoprofilaktika=Epidemiology and Vaccination. 2015; 14(3):74—84. (in Russ.). doi:10.31631/2073-3046-2015-14-3-74-83

3. Savenkova M.S., Isaeva E.I., Vetrova E.N., Kraseva G.N., Abramova N.A., Shabat M.B., et al. Role of antiviral therapy in respiratory infections in children: analysis of clinical and laboratory observations. Vopr. prakt. pediatr. = Clinical Practice in Pediatrics; 2022; 17(6):45—54. (in Russ.). doi: 10.20953/1817-7646-2022-6-45-54

4. Geppe N.A., Gorelov A.V., Kozlova L.V. Kondyurina Ye.G., Malakhov A.B. Acute respiratory tract infections in children. Diagnosis, therapy, prevention: a clinical guidance. M.: MedCom-Pro; 2018:254. (in Russ.)

5. Holsemer N., Nasvold J.J., Pohl K.J. Human metapneumovirus infection in hospitalized children. Respir. Care, 2020; 65(5):650—657. doi: 10.4187/respcare.07156

6. To K.K.W., Yip C.C.Y, Yuen K.Y. Rhinovirus — from bench to bedside. J. Formosan Med. Assoc. 2017; 116(7):496—504. doi:10.1016/j.jfma.2017.04.009

7. Kaluzhskikh T.I., Savinykh N.A., Savinykh M.V., Utenkova E.O. Features of metapneumovirus and bocavirus infections in children. Detskie Infektsii=Children's Infections. 2020; 19(3):12—14. (in Russ.) doi:10.22627/2072-8107-2020-19-3-12-14

8. Harlamova F.S., Kladova O.V., Uchajkin V.F. Cheshik S.G, Vartanyan R.V., Zvereva N.N. Clinical efficacy of an interferon inducer in metapneumovirus and bocavirus respiratory infections in children. Zhurnal infektologii=Journal Infectology; 2017; 9(1):17—21. (in Russ.). https://journal.niidi.ru/jofin/article/view/549/507

9. Barr R., McGalliard R., Drysdale S. Human metapneumovirus in paediatric intensive care unit admissions in the United Kingdom 2006—2014. J. Clin. Virol. 2019; 112:15—19. doi: 10.1016/j.jcv.2019.01.006

10. Сhoi M.J., Song J.Y., Yang T.U., Jeon J.H., Noh J.Y., HongK.W.et al. Acute myopericarditis caused by human metapneumovirus. Infect. Chemother. 2016; 48(1):36—40. doi: 10.3947/ic.2016.48.1.36

11. Naz R., Gut A., Urooj J., Urooj A., Amin S., Fatima Z. Etiology of acute viral respiratory infections common in Pakistan: A review. Rev. Med. Virol. 2018; 29(2):e2024. doi: 10.1002/rmv.2024

12. Hamelin M.E., Abed Y., Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin. Infect. Dis. 2004; 38:983—990. doi: 10.1086/382536

13. Esposito S., Mastrolia M.V. Metapneumovirus infections and respiratory complications. Semin. Respir. Crit. Care Med. 2016; 37(4):512—521. doi:10.1055/s-0036-1584800

14. Narogan M.V., Ryumina I.I., Nepsha O.S., Burmenskaya O.V., Zubkov V.V. Metapneumovirus infection in premature infant with extremely low birth weight. Clinical case. Neonatologiya: novosti, mneniye, оbucheniye=Neonatology: News, Opinions, Training; 2016; 2:97—102. (in Russ.).

15. Yatsyshina S.B. Pneumoviruses in human infectious diseases. Zhurnal microbiol. epidemiol. immunobiol.=Zh. Mikrobiol. 2017; 6:95—105. (in Russ.). doi:10.36233/0372-9311-2017-6-95-105

16. Russell C.J., Penkert R.R., Kim S., Hurwitz J.L. Human metapneumovirus: a largely unrecognized threat to human health. Рathogens. 2020; 9(2):109. doi:10.3390/pathogens9020109

17. Williams J.V., Wang C.K., Yang C.F. Tollefson S.J., House F.S., Heck J.M. et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J. Inf. Dis. 2006; 163(3):387—395. doi: 10.1086/499274

18. Sharipova E.V., Babachenko I.V., Orlova E.D. Metapneumovirus infection in children. Pediatr=Pediatrician. 2020; 11(5):13—19. (in Russ.)

19. Sharipova E.V., Babachenko I.V., Levina A.S., Grigoriev S.G. Antiviral therapy of acute respiratory viral infection and influenza in children in a hospital. Zhurnal infektologii=Journal Infectology. 2018; 10(4):82—88. (in Russ.) DOI: 10.22625/2072-6732-2018-10-4-82-88

20. Determination of interferon status, as an indicator of non-specific resistance of the human body: Practical recommendations of the Association of laboratory and organizations «Federation of Laboratory Medicine». Еd. by academician of RAS, Professor F.I. Ershov. Moscow, 2018:26. (in Russ). https://fedlab.ru/upload/medialibrary/bc9/Prakt-rek-IFN-status_-FLM_-2018.pdf

21. Burtseva E.I., Kolobukhina L.V., Voronina O.L., Ignatjeva A.V., Mukasheva E.A., Panova A.D. et al. Features of the circulation of ARVI pathogens during of emergence and widespread of SARS-CoV-2 in the 2018—2021. Epidemiologiya i Vaktsinoprofilaktika=Epidemiology and Vaccinal Prevention. 2022; 21(4):16—26. (In Russ.). doi:10.31631/2073-3046-2022-21-4-16-26

22. Sominina A.A., Danilenko D.M., Stolyarov K.A., Karpova L.S., Bakaev M.I., Levanyuk T.P., Burtseva E.I., Lioznov D.A. Interference of SARS-CoV-2 with other Respiratory Viral infections agents during pandemic. Epidemiologiya i Vaktsinoprofilaktika=Epidemiology and Vaccinal Prevention. 2021; 20(4):28—39. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-4-28-39